CO2 Solutions Announces U.S. Patent Allowance

News - CO2 Solutions announceS it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application No. 13/264,294 entitled Process for CO2 Capture Using Micro-Particles Comprising Biocatalysts. The Corporation also takes this opportunity to provide an update on the depth and breadth of its U.S. intellectual property portfolio in context of the landmark announcement made this week by the U.S. Environmental Protection Agency (EPA) on the regulation of carbon emissions from existing power plants.

12 International Events choose Québec City

News - Some, 9,000 delegates will visit the Québec City Convention Centre, generating $19 M in economic spinoffs and 25,000 room nights. Of the 9,000 delegates, 4,000 work in artificial intelligence, neuroscience and cognitive sciences, proving that Québec City is a scientific and intellectual hub.

Healthy tissue grafted to the brains of Huntington’s patients also develops signs of the disease

News - A recent study published in Annals of Neurology reports that healthy human tissue grafted to the brains of patients with Huntington’s disease in the hopes of treating the neurological disorder also developed signs of the illness, several years after the graft. This discovery will have profound implications on our understanding of the disease and how to treat it, and may also lead to the development of new therapies for neurodegenerative disorders.

A smart home insurance tool offered by SSQauto - Property inventory at your fingertips

News - Completing an inventory of your possessions may be very practical, but it can be a long and tedious process that few can claim to have completed. Fortunately, thanks to SSQauto's new property inventory tool, making a list of your possessions can now be easy, fast and most importantly, fun.

Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer

News - Aeterna Zentaris announceS that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer.

Quebec City business brings smart TV experience to a hotel near you

News - The Business Development Bank of Canada (BDC) announced today that the turning-point project, "Room with a View," submitted by local businessman Louis-Philippe Noel, will represent Quebec in the finals of the 2014 BDC Young Entrepreneur Award (BDC YEA).

International contract for Ocean Dredging DSM in the Dominican Republic

News - Ocean Dredging DSM inc. was awarded the contract for maintenance dredging of the port of San Pedro de Macoris, the capital of the region of the same name, in the Dominican Republic. The contract for the extraction of 35,000 m3 will be spread over 11 days from May 28, 2014. Dredging aimed at restoring depths by removing accumulations of sediment using the trailing suction hopper dredge OCEAN NORTH TRAVERSE.

The Genomics Center of the Centre de recherche du CHU de Québec - A center of international caliber, focused on excellence and efficiency

News - The Genomics Center of the Centre de recherche du CHU de Québec, with its high-tech equipment, offering services to over 300 research teams each year, was officially inaugurated today. This center enables research professionals from the CHU de Québec, affiliated with Université Laval, to maintain and develop their acquired leadership in this cutting-edge area of genomics.

INO awarded for its successes in the field of technology commercialization

News - The National Optics Institute (INO) announces that it received the Celestica Award for Technology Commercialization from the Canadian Advanced Technology Alliance (CATAAlliance), the largest high-tech association in Canada, at the 29th Innovation and Leadership Awards Gala on May 21 at Carleton University in Ottawa.

Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO

News - Aeterna Zentaris announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial.


Subscribe to our newsletter for interesting news and information.

Print this page